TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04561557

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CT103A cells
Description: Subjects will undergo leukapheresis to isolate peripheral blood mononuclear cells (PBMCs) to manufacture CT103A cells, during which cyclophosphamide will be administered for the purpose of lymphocytes depletion. After lymphodepletion, subjects will receive one dose treatment with CT103A cells by intravenous (IV) infusion. The initial dose of 0.5×10\^6 CAR+ T cells/kg will be infused on day 0.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CT103A cells
Description: Subjects will undergo leukapheresis to isolate peripheral blood mononuclear cells (PBMCs) to manufacture CT103A cells, during which cyclophosphamide will be administered for the purpose of lymphocytes depletion. After lymphodepletion, subjects will receive one dose treatment with CT103A cells by intravenous (IV) infusion. The initial dose of 0.5×10\^6 CAR+ T cells/kg will be infused on day 0.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide and fludarabine
Description: Subjects will receive one 3-day cycle of lymphodepletion starting 4 days prior to CT103A infusion on Day 0.~Subjects will be given IV infusion of cyclophosphamide 300 mg/m2/day on day -4, -3 and -2, and fludarabine 30 mg/m2 over 30 minutes administered immediately after cyclophosphamide.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide and fludarabine
Description: Subjects will receive one 3-day cycle of lymphodepletion starting 4 days prior to CT103A infusion on Day 0.~Subjects will be given IV infusion of cyclophosphamide 300 mg/m2/day on day -4, -3 and -2, and fludarabine 30 mg/m2 over 30 minutes administered immediately after cyclophosphamide.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide and fludarabine
Description: Subjects will receive one 3-day cycle of lymphodepletion starting 4 days prior to CT103A infusion on Day 0.~Subjects will be given IV infusion of cyclophosphamide 300 mg/m2/day on day -4, -3 and -2, and fludarabine 30 mg/m2 over 30 minutes administered immediately after cyclophosphamide.
Study: NCT04563884

Intervention type: OTHER
Intervention: Questionnaires
Description: Children 12 months to 5 years old will receive PEACH alone, children 5 years old to 11 years old will receive PEACH and SSQ-P, and children and adolescents over 11 years old will receive SSQ-P and SSQ-C (even between 11 and 13 years old, the PEACH also).~Questionnaires will be completed twice, 15 days apart.

Intervention type: OTHER
Intervention: Questionnaires
Description: Children 12 months to 5 years old will receive PEACH alone, children 5 years old to 11 years old will receive PEACH and SSQ-P, and children and adolescents over 11 years old will receive SSQ-P and SSQ-C (even between 11 and 13 years old, the PEACH also).~Questionnaires will be completed twice, 15 days apart.
Study: NCT01725269

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AIR001
Description: All doses specified are the amount loaded into the I-neb AAD System nebulizer.
Study: NCT03454165

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: BNC105P
Description: BNC105P is the phosphate ester of BNC105, a small molecule tubulin polymerization inhibitor.

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Ibrutinib
Description: A novel BTK inhibitor.
Study: NCT03857568

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR0410
Description: drug will be dosed repeatedly

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo will be dosed repeatedly
Study: NCT03633929

Intervention type: OTHER
Intervention: KIOS OUD
Description: Study Participants will evaluate software known as KIOS-OUD
Study: NCT03404102

Intervention type: DEVICE
Intervention: Cu-IUD
Description: Copper Intra-uterine device used as contraceptive method

Intervention type: DEVICE
Intervention: Cu-IUD
Description: Copper Intra-uterine device used as contraceptive method
Study: NCT01495884

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: non-pegylated liposomal doxorubicon (Myocet™)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lapatinib (Tyverb™)
Study: NCT04119453

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rivoceranib
Description: Film-coated tablets
Study: NCT00738686

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intracoronary stent implantation
Description: Taxus stent implantation in patients with multivessel coronary artery disease
Study: NCT04566003

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [18F]GTP1
Description: Participants will receive a bolus IV of approximately 7mCi of \[18F\]GTP1 radiotracer.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [18F]GTP1
Description: Participants will receive a bolus IV of approximately 7mCi of \[18F\]GTP1 radiotracer.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [18F]PI-2620
Description: Participants will receive a bolus IV of approximately 5mCi of \[18F\]PI-2620 radiotracer.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [18F]MK-6240
Description: Participants will receive a bolus IV of approximately 5mCi of \[18F\]MK-6240 radiotracer.
Study: NCT01961154

Intervention type: DRUG
Group type: OTHER
Intervention: Asthma medication reduction
Description: The asthma medications will be reduced in three steps up to total cessation of asthma drugs or up to asthma exacerbation. First step: Long-acting beta-agonist will be discontinued. The use of inhaled corticosteroids is continued, using the same dosage, preparation, and inhaler as before, for six weeks. Second step: medium to high daily inhaled corticosteroids dose is reduced to low daily dose, for six weeks. Third step: low inhaled corticosteroids dose will be stopped, for six weeks. Before each reduction, saline challenge will be performed.
Study: NCT01949844

Intervention type: DRUG
Group type: OTHER
Intervention: regadenoson
Description: Lexiscan® is being used off-label. The FDA Issued IND # is 119898. For the cardiac MRI, Lexiscan® will be used at the same dosage and administration as prescribed in the package insert - 5 mL (0.4 mg regadenoson) as packaged and supplied by the manufacturer, Astellas Pharma U.S., in single-use pre-filled syringes administered by rapid intravenous injection, followed immediately by saline flush.

Intervention type: DRUG
Group type: OTHER
Intervention: Optimark®
Description: For the cardiac MR, the contrast agent, Optimark® is administered as a bolus peripheral intravenous injection at a dose of 0.2 mL/kg (0.1 mmol/kg) and at a rate of 1 to 2 mL/sec delivered by manual injection.

Intervention type: DEVICE
Group type: OTHER
Intervention: Myocardial perfusion MRI
Study: NCT03651427

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Estradiol
Description: Induced hypogonadism and re-institution of CSHT
Study: NCT00756236

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metoprolol
Description: 60ml syringes of 0.9% NaCl, 5ml syringes of metoprolol at 1mg/ml concentration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esmolol
Description: 60ml syringes of esmolol at 10 mg/ml concentration, 5ml syringes of 0.9% of NaCl

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: P-Group
Description: 0.9%NaCl dispensed in 60ml \& 5ml syringes
Study: NCT00186979

Intervention type: DRUG
Group type: OTHER
Intervention: Irinotecan, ZD1839, Vincristine, Cefixime, Cefpodoxime.
Description: See Detailed Description section for details of treatment interventions.
Study: NCT01105702

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lithium Carbonate
Study: NCT01077037

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Decision Aid
Description: Chest pain choice decision aid
Study: NCT01105702

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation
Study: NCT01951612

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Executive Function Training Program
Description: Participants will take part in ten 2-hour sessions over 5 weeks.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Psychoeducational Training Program
Description: Participants will take part in ten 2-hour sessions over 5 weeks.
Study: NCT02355821

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Moxonidine
Description: 0.4 mg moxonidine QD titration up to 0.6 mg moxonidine BID Other Names:perindopril 10 mg/day (optional); losartan 50 mg/day (optional); calcium carbonate; vitamin D

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bisoprolol
Description: 5 mg Bisoprolol QD titration up to 7.5 mg Bisoprolol BID Other Names: perindopril 10 mg/day (optional); losartan 50 mg/day (optional); calcium carbonate; vitamin D
Study: NCT00585845

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CRS-207, Live-attenuated Listeria monocytogenes expressing human Mesothelin
Description: 2-hour IV infusion once every 21 days, up to 4 doses. Doses from 1x10\^8 cfu to 1x10\^10 cfu.
Study: NCT00643825

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Temozolomide
Description: Capsules 5,10,20,100,250 mg 200mg/m2/day , 5days per 28 till PD

Intervention type: DRUG
Group type: OTHER
Intervention: Temozolomide
Description: Observation till Progression then rechallenging with TMZ
Study: NCT04427475

Intervention type: DRUG
Group type: OTHER
Intervention: pabolizumab
Description: 100 patients with stage IV EGFR / ALK wild-type NSCLC (squamous cell carcinoma patients do not need to be detected) who received anti-PD-1 (pabolizumab) treatment combined with chemotherapy as the first-line treatment were enrolled in the center. Baseline plasma samples were collected before the treatment, and the efficacy was evaluated once every two treatment cycles. At the same time, plasma samples were collected at key nodes until the patient's progress.

Intervention type: DRUG
Group type: OTHER
Intervention: nafulizumab
Description: nafulizumab
Study: NCT03826264

Intervention type: PROCEDURE
Intervention: TAVR
Description: transcatheter aortic valve replacement (TAVR)

Intervention type: PROCEDURE
Intervention: TAVR
Description: transcatheter aortic valve replacement (TAVR)

Intervention type: PROCEDURE
Intervention: TAVR
Description: transcatheter aortic valve replacement (TAVR)

Intervention type: PROCEDURE
Intervention: TAVR
Description: transcatheter aortic valve replacement (TAVR)
Study: NCT03512717

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Potenfill
Description: Maximum: 22ml

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Powerfill
Description: Maximum: 22ml
Study: NCT06048562

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: echocardiography
Description: evaluation idm for cardiomyopathy by echo
Study: NCT03069261

Intervention type: DEVICE
Intervention: Indocyanine green angiography
Study: NCT03513809

Intervention type: DEVICE
Intervention: Thoracic electrical impedance tomography
Description: Non invasive, radiation-free, bedside monitoring tool for distribution of pulmonary ventilation.
Study: NCT04308902

Intervention type: OTHER
Intervention: VLBW
Description: Participants previously enrolled in the Bovine vs. Human Milk-Based Fortifier Study
Study: NCT02200536

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Infant oral health promotion package
Description: Infant oral health promotion package includes an infant oral health pamphlet, a baby toothbrush, fluoride toothpaste (1000 ppm) and a trainer cup.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Infant oral health pamphlet
Description: Infant oral health pamphlet
Study: NCT02591901

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Uro vaxom
Description: Prevention of recurrent symptomatic lower urinary tract infections

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo comparator
Description: Placebo comparator
Study: NCT05130710

Intervention type: PROCEDURE
Intervention: staging laparoscopy
Description: All patients of both groups underwent staging laparoscopy by the same two attending onco-surgeon, using the same technique and the same laparoscopic device. Under general anesthesia and in supine position SL was performed. A 10 mm optic laparoscopic port was inserted via the midline incision below the umbilicus using Hasson technique. All four quadrants of the abdomen as well as pelvis were inspected during laparoscopy and biopsy was taken from any suspicious lesion through insertion of 5mm port. All specimens underwent cytological evaluation by two independent pathologists. The presence of any malignant cells, regardless of the number, confirmed the positive cytology. In the event of discordant reports between two pathologists, specimens were sent for the third review by a pathologist who was blinded to the previous results. Laparoscopic evaluation was considered positive as if adjacent organ involvement, omental involvement or peritoneal seeding were seen.

Intervention type: PROCEDURE
Intervention: staging laparoscopy
Description: All patients of both groups underwent staging laparoscopy by the same two attending onco-surgeon, using the same technique and the same laparoscopic device. Under general anesthesia and in supine position SL was performed. A 10 mm optic laparoscopic port was inserted via the midline incision below the umbilicus using Hasson technique. All four quadrants of the abdomen as well as pelvis were inspected during laparoscopy and biopsy was taken from any suspicious lesion through insertion of 5mm port. All specimens underwent cytological evaluation by two independent pathologists. The presence of any malignant cells, regardless of the number, confirmed the positive cytology. In the event of discordant reports between two pathologists, specimens were sent for the third review by a pathologist who was blinded to the previous results. Laparoscopic evaluation was considered positive as if adjacent organ involvement, omental involvement or peritoneal seeding were seen.
Study: NCT01931956

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MitraClip® implant
Description: Percutaneous mitral valve repair using MitraClip implant

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MitraClip® implant
Description: Percutaneous mitral valve repair using MitraClip implant

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MitraClip® implant
Description: Percutaneous mitral valve repair using MitraClip implant

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MitraClip® implant
Description: Percutaneous mitral valve repair using MitraClip implant
Study: NCT01757938

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Shang Ring Guided Circumcision

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Forceps Guided Circumcision
Study: NCT02310425

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: S. boulardii
Description: 50 mg/kg twice daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: he control group (group C) did not receive S. boulardii (nor other probiotics)
Study: NCT01088178

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Levonorgestrel Intrauterine System (LNG-IUS: Mirena, Bayer)
Description: Placement of Mirena at given intervals during the postpartum period
Study: NCT04308902

Intervention type: OTHER
Intervention: Term-born Comparison
Description: Children born \>=37 weeks gestation and weighing more than 2500g
Study: NCT01088178

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Levonorgestrel Intrauterine System (LNG-IUS: Mirena, Bayer)
Description: Placement of Mirena at given intervals during the postpartum period

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Levonorgestrel Intrauterine System (LNG-IUS: Mirena, Bayer)
Description: Placement of Mirena at given intervals during the postpartum period
Study: NCT01999543

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: plant-based dietary supplement

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: plant-based dietary supplement

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: plant-based dietary supplement

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: plant-based dietary supplement

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo

Intervention type: OTHER
Group type: OTHER
Intervention: Placebo
Study: NCT02109861

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melphalan
Description: A microdose of 2 mg/m2 iv Melphalan (1% of standard dose) is given two hours prior to planned standard dose Melphalan

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Description: A microdose of 0.013 mg/m2 iv Bortezomib (1% of standard dose) is given two hours prior to planned standard dose Bortezomib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: A microdose of 0.4 mg iv Dexamethasone (1% of standard dose) is given two hours prior to planned standard dose of Dexamethasone
Study: NCT01046058

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TMC435
Description: 150 mg (two 75-mg capsules) orally (by mouth) once daily for 7 days
Study: NCT00185640

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclosporine
Description: Starting day -3 at a dose of 5 mg/kg orally twice daily with a target trough level of 350 to 450 ng/mL

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anti-thymocyte globulin (ATG)
Description: 1.5 mg/kg for total dose of 7.5mg/kg, IV starting on day -11 to day -7 before HCT

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil (MMF)
Description: Begins on day 0 after HCT at a dose of 15 mg/kg. Transplant recipients who received related donor grafts received MMF twice daily and those who received unrelated donor grafts received MMF 3 times daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Filgrastim
Description: * Donors mobilized with 16 µg/kg/day filgrastim.~* As needed, myelosuppression in transplant recipients will be managed with subcutaneous filgrastim 5 µg/kg/day

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Total Lymphoid Irradiation (TLI)
Description: 0.8 Gy/day from day -11 to day -7 (inclusive) from day -4 to day -2 (inclusive) with 2 additional fractions of 0.8 Gy delivered on day -1 for total dose of 8 Gy.
Study: NCT04256356

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Feeding infants with formula milk with fermented matrix at dosage of 4.6 g per 100g of powder
Description: Infants enrolled were fed either with formula milk with fermented matrix at double dosage or with formula milk with fermented matrix at triple dosage or with standard formula during the first 3 months of life. Breastfed infants were the reference group.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Feeding infants with formula milk with fermented matrix at dosage of 6.9 g per 100g of powder
Description: Infants enrolled were fed either with formula milk with fermented matrix at double dosage or with formula milk with fermented matrix at triple dosage or with standard formula during the first 3 months of life. Breastfed infants were the reference group.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Feeding infants with standard formula milk
Description: Infants enrolled were fed either with formula milk with fermented matrix at double dosage or with formula milk with fermented matrix at triple dosage or with standard formula during the first 3 months of life. Breastfed infants were the reference group.

Intervention type: OTHER
Group type: OTHER
Intervention: Breastfeeding infants
Description: reference group
Study: NCT00641914

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: budesonide

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT03406585

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ProTrans: Allogeneic transplantation with WJMSCs
Description: The drug is a cell suspension with allogeneic mesenchymal stromal cells derived from umbilical cord tissue.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: Placebo treatment
Study: NCT01334671

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin
Description: Group 1:80mg before PCI and 40mg per day after PCI for one month then 20mg per day until the end of the trial Group 2:40mg per day after PCI for one month then 20mg per day until the end of the trial Group 3:20mg per day after PCI until the end of the trial

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin
Description: Group 1:80mg before PCI and 40mg per day after PCI for one month then 20mg per day until the end of the trial Group 2:40mg per day after PCI for one month then 20mg per day until the end of the trial Group 3:20mg per day after PCI until the end of the trial

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin
Description: Group 1:80mg before PCI and 40mg per day after PCI for one month then 20mg per day until the end of the trial Group 2:40mg per day after PCI for one month then 20mg per day until the end of the trial Group 3:20mg per day after PCI until the end of the trial
Study: NCT00965978

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ONO-5920 / YM529
Description: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ONO-5920 / YM529
Description: oral
Study: NCT02780726

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: roxadustat
Description: Oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: roxadustat
Description: Oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: roxadustat
Description: Oral
Study: NCT03830203

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAT1806
Description: 8 mg/kg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Actemra(EU-licensed)
Description: 8 mg/kg
Study: NCT03707639

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apatinib
Description: Apatinib (500 mg qd p.o.) until disease progression or intolerable toxicity or refused by the patients.
Study: NCT02573415

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Uterus Transplant
Description: transplant of a deceased donor uterus.
Study: NCT02358096

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP8232
Description: oral capsule

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: oral capsule
Study: NCT03707639

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: POF
Description: The POF regimen consisted of a 3-hour infusion of paclitaxel (135 mg/m2) followed by oxaliplatin (85 mg/m2) and Calcium Levofolinate (200 mg/m2).Subsequently, a 46-hour infusion of fluorouracil (2400 mg/m2) was administered using an ambulatory pump, repeating the cycle every 14 days.
Study: NCT03767270

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MRT5201
Description: Codon-optimized human ornithine transcarbamylase messenger ribonucleic acid with lipid-based nanoparticles

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 5% dextrose in water